潜伏性结核感染治疗中出现流感样反应者抗利福喷汀和异烟肼抗体评估
本研究基于PREVENT TB试验,评估接受每周异烟肼联合利福喷汀3个月(3HP)或每日异烟肼9个月(9H)治疗者中流感样反应与抗利福喷汀、异烟肼等抗体的关联。128名参与者中,3HP组22例有流感样反应、47例对照,9H组12例有反应、47例对照。抗体阳性比例低,且在有反应者与无反应者间无显著差异,提示3HP和9H相关流感样反应非抗体介导。
要点
- 3HP组抗利福喷汀IgG阳性率:有反应者2/22(9%)vs 对照6/47(13%),P = .7。
- 9H组有反应者均未检出抗异烟肼抗体,对照组IgG和IgM各4/47(9%)。
- 抗体阳性比例低且组间无差异,提示流感样反应非抗体介导。
核心结论
- 检测到抗利福喷汀、抗异烟肼和抗利福喷汀代谢物抗体,但抗体阳性比例低,且在有流感样反应者与无反应者间无差异,提示3HP和9H相关流感样反应非抗体介导。
研究设计与样本
- 评估PREVENT TB研究参与者,接受每周异烟肼联合利福喷汀3个月(3HP)或每日异烟肼9个月(9H)治疗结核分枝杆菌感染。
- 流感样反应定义为任何流感样症状等级≥2级;对照为未报告流感样反应者。
- 开发竞争性酶联免疫吸附试验(ELISA)检测抗利福喷汀、异烟肼、利福平和利福喷汀代谢物抗体。
- 共128名参与者:69名接受3HP(22例有流感样反应,47例对照),59名接受9H(12例有反应,47例对照)。
主要发现
- 3HP组:抗利福喷汀IgG在有反应者中2/22(9%),对照组6/47(13%),P = .7;抗异烟肼IgG在有反应者中2/22(9%),对照组4/47(9%),P = .9。
- 9H组:抗异烟肼IgG和IgM在对照组各4/47(9%),有反应者中均未检出;抗利福喷汀IgG在有反应者和对照组中均未检出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Flu-like reactions can occur after exposure to rifampin, rifapentine, or isoniazid. Prior studies have reported the presence of antibodies to rifampin, but associations with underlying pathogenesis are unclear. METHODS: We evaluated PREVENT TB study participants who received weekly isoniazid plus rifapentine for 3 months (3HP) or daily isoniazid for 9 months (9H) as treatment for Mycobacterium tuberculosis infection. Flu-like reaction was defined as a grade ≥2 of any of flu-like symptoms. Controls (3HP or 9H) did not report flu-like reactions. We developed a competitive enzyme-linked immunosorbent assays (ELISA) to detect antibodies against rifapentine, isoniazid, rifampin, and rifapentine metabolite. RESULTS: Among 128 participants, 69 received 3HP (22 with flu-like reactions; 47 controls) and 59 received 9H (12 with flu-like reactions; 47 controls). In participants receiving 3HP, anti-rifapentine IgG was identified in 2 of 22 (9%) participants with flu-like reactions and 6 of 47 (13%) controls (P = .7), anti-isoniazid IgG in 2 of 22 (9%) participants with flu-like reactions and 4 of 47 (9%) controls (P = .9). Among participants receiving 9H, IgG and IgM anti-isoniazid antibodies were each present in 4 of 47 (9%) controls, but none among participants with flu-like reactions; anti-rifapentine IgG antibodies were not present in any participants with flu-like reactions or controls. CONCLUSIONS: We detected anti-rifapentine, anti-isoniazid, and anti-rifapentine metabolite antibodies, but the proportions of participants with antibodies were low, and did not differ between participants with flu-like reactions and those without such reactions. This suggests that flu-like reactions associated with 3HP and 9H were not antibody mediated. CLINICAL TRIALS REGISTRATION: NCT00023452.
引用
- Moro RN, Mehaffy C, De P, et al. Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection. J Infect Dis. 2024. PMID: 38640958. doi:10.1093/infdis/jiae180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。